{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hepatitis-b/prescribing-information/anti-pruritics/","result":{"pageContext":{"chapter":{"id":"1576eb24-e96c-50e6-9976-05164be1127e","slug":"anti-pruritics","fullItemName":"Anti-pruritics","depth":2,"htmlHeader":"<!-- begin field 5a8d2169-1486-4888-ac69-2df34dc621f2 --><h2>Anti-pruritics</h2><!-- end field 5a8d2169-1486-4888-ac69-2df34dc621f2 -->","summary":"","htmlStringContent":"<!-- begin item d88e3c13-2ee8-4f2f-9816-39c36a6ec2b3 --><!-- end item d88e3c13-2ee8-4f2f-9816-39c36a6ec2b3 -->","topic":{"id":"f75dcfde-3cb4-5059-94df-19d53a6c28e9","topicId":"4fc86266-0752-4667-994f-7f6fc7e46056","topicName":"Hepatitis B","slug":"hepatitis-b","lastRevised":"Last revised in November 2019","chapters":[{"id":"986057cd-07a1-565e-9c7a-d3b3dc88368d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2331f5c5-fb51-54d1-b722-946b4f34a693","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"653459fe-510a-5a1a-92dc-8197c598c85e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"12e8fb8c-9424-5f20-90e5-65e823f603c3","slug":"changes","fullItemName":"Changes"},{"id":"2299e2ba-3fb3-5f37-9c6b-63ec8dbbffd6","slug":"update","fullItemName":"Update"}]},{"id":"c14d3383-629b-5bd6-b6c0-318bbcf86fb2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"58e5cd67-9ca7-5bfe-b2b6-bf4372ac895f","slug":"goals","fullItemName":"Goals"},{"id":"a1abbdfd-238b-55b7-8de2-09fd4ff6065b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fc44420e-13ab-526e-a0c7-ef2f93cce77b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b59d4642-5914-585b-82b1-6f7989cef100","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"af246587-2615-513e-aafc-3ea762d8aab7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bba17b9f-47f8-52cf-a8e7-111c1a5094a2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2c6fa000-50a2-5823-9acb-0bd808dc51e6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"dfcb6ed4-783a-5fbc-9259-096762bb7c69","slug":"definition","fullItemName":"Definition"},{"id":"e06f78dc-080c-542f-b450-356db08c00a9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0c1d15cf-36ee-5c84-ad7c-e06836a161c0","slug":"transmission","fullItemName":"Transmission"},{"id":"939f1d6a-6b15-5c4f-91c8-9164e800cd87","slug":"people-at-high-risk-of-hepatitis-b","fullItemName":"People at high risk of hepatitis B"},{"id":"d452f04a-7d9d-5739-9cb9-f583eb136f3a","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"b3642d36-7175-548b-b6f0-d694e7397bd3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6acbd5e1-b0e6-527b-bad0-42c21a928d1e","slug":"when-to-test-for-hepatitis-b","fullItemName":"When to test for hepatitis B"},{"id":"706362c9-e255-511b-83b4-74b853c926c7","slug":"how-to-test-for-hepatitis-b","fullItemName":"How to test for hepatitis B"},{"id":"c0c1ae56-2316-56eb-ad65-4b85e982fc11","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"41c2681f-bf40-5b08-a518-32f2ab1206fb","fullItemName":"Management","slug":"management","subChapters":[{"id":"b2d949a2-a42f-5c0a-a955-414bac741bd3","slug":"prevention-of-infection-with-hepatitis-b","fullItemName":"Scenario: Prevention of infection with Hepatitis B"},{"id":"00ed825c-5927-50f5-940d-94d6b4001150","slug":"managing-hepatitis-b-infection","fullItemName":"Scenario: Managing hepatitis B infection"}]},{"id":"c7941282-a3b2-5716-b0cc-80cb243a7405","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8df28bde-0bc5-533e-a54b-507fd3ceee61","slug":"hepatitis-b-vaccine","fullItemName":"Hepatitis B vaccine"},{"id":"c7099851-c102-56f2-b063-021f3d00b880","slug":"analgesics","fullItemName":"Analgesics"},{"id":"6a9675fd-5496-5ca4-9a76-36ee6cc93a25","slug":"anti-emetics","fullItemName":"Anti-emetics"},{"id":"1576eb24-e96c-50e6-9976-05164be1127e","slug":"anti-pruritics","fullItemName":"Anti-pruritics"}]},{"id":"3c7651c1-b246-51db-85b3-e1b6713a47bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"548463b9-9c49-5154-bad9-fe10668804da","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8b3032fc-e20a-509b-b390-81cef2509ded","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5e0cdb38-e518-5a0c-9215-493c78f74377","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3e63144c-a0f3-5eb1-980d-a219e8a53633","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"94d851c4-3314-5a3d-801a-0a208e287514","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4df2edc1-d17c-57d1-a914-4100299c8f7d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cecf6c0b-d134-54cb-abef-c2ccab9effb6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c7941282-a3b2-5716-b0cc-80cb243a7405","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8786c8fa-fa6c-53d6-b5bf-44ff575ce4c5","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field f9342ada-2c53-4662-a977-aafe01450ef5 --><h3>Contraindications and cautions</h3><!-- end field f9342ada-2c53-4662-a977-aafe01450ef5 -->","summary":"","htmlStringContent":"<!-- begin item 9c211e1f-1b4a-4874-8e11-aafe01450ea0 --><!-- begin field dddc0a25-36b8-40fd-9aca-aafe01450ef5 --><h4>Chlorphenamine</h4><ul><li><strong>Sedating antihistamines should be used with caution </strong><strong>in people with:</strong><ul><li>Liver dysfunction — chlorphenamine can be used in people whose metabolic and synthetic function is unaffected (such as in mild hepatitis). However, seek specialist advice before using chlorphenamine in people with moderate hepatic impairment. It must be avoided in people with severe hepatic impairment, such as those with cirrhosis or encephalopathy who may decompensate, because of its sedative effects.</li><li>Urinary retention, prostatic hypertrophy, angle-closure glaucoma, or pyloroduodenal obstruction — if possible, avoid using sedating antihistamines because of their significant antimuscarinic activity (particularly in elderly people).</li><li>Epilepsy — avoid chlorphenamine if possible, as it may reduce the seizure threshold.</li><li>Pregnancy — There is currently no evidence of an increased risk of fetal toxicity following chlorphenamine use in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">UKTIS, 2019b</a>].</li><li>Breastfeeding — the UK Drugs in Lactation Advisory Service states that if a sedating antihistamine is needed, chlorphenamine is preferred due to extensive clinical experience of safe use in breastfeeding. There is a possible risk of sedation in the infant, who should be monitored for drowsiness. The Summary of Product Characteristics for chlorphenamine states that it should not be used in breastfeeding unless considered medically essential. See the <a data-hyperlink-id=\"a00e3c8f-bef5-4025-bda1-a99300077ba3\" href=\"http://www.midlandsmedicines.nhs.uk/\">UKMI lactation advisory service</a> website for more information.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">North-Lewis, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field dddc0a25-36b8-40fd-9aca-aafe01450ef5 --><!-- end item 9c211e1f-1b4a-4874-8e11-aafe01450ea0 -->","subChapters":[]},{"id":"6a337b34-771c-57cb-8d34-6406fca09eea","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d00d9e4d-ea0f-4aad-b8c3-aafe01451df5 --><h3>Adverse effects</h3><!-- end field d00d9e4d-ea0f-4aad-b8c3-aafe01451df5 -->","summary":"","htmlStringContent":"<!-- begin item cb4ab787-6c13-4903-9cd2-aafe01451db5 --><!-- begin field 3a450d7f-2230-420a-b423-aafe01451df5 --><ul><li><strong>The most commonly reported adverse effects </strong>are nervous system disorders:<ul><li>Elderly people are particularly susceptible (and so lower doses are recommended).</li><li>Sedating antihistamines may cause drowsiness.</li><li>Anticholinergic adverse effects may also occur, for example, blurred vision and dry mouth.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">ABPI, 2016</a>]</p><!-- end field 3a450d7f-2230-420a-b423-aafe01451df5 --><!-- end item cb4ab787-6c13-4903-9cd2-aafe01451db5 -->","subChapters":[]},{"id":"1d8f66d6-d9fc-52b6-98c7-8fec7cc12500","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e602544a-5834-4588-b890-aafe01452ad4 --><h3>Drug interactions</h3><!-- end field e602544a-5834-4588-b890-aafe01452ad4 -->","summary":"","htmlStringContent":"<!-- begin item 73078d8d-fea4-4af1-9ee9-aafe01452a96 --><!-- begin field 621ad8cc-2a41-4f63-8355-aafe01452ad4 --><p><strong>Key drug interactions with chlorphenamine include:</strong></p><ul><li><strong>Hypnotics and anxiolytics </strong>— increased sedative effects.</li><li><strong>Phenytoin</strong> — chlorphenamine inhibits phenytoin metabolism and can lead to phenytoin toxicity.</li><li><strong>MAOIs </strong>—the anticholinergic effects of chlorphenamine are intensified by MAOIs. Do not prescribe chlorphenamine to a person who has been treated with MAOIs within the last fourteen days.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 621ad8cc-2a41-4f63-8355-aafe01452ad4 --><!-- end item 73078d8d-fea4-4af1-9ee9-aafe01452a96 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}